Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

R.P. Riechelmann, V. Srimuninnimit, R. Bordonaro, P. Kavan, M. Di Bartolomeo, E. Maiello, I. Cicin, P. García-Alfonso, I. Chau, M.Y. Fedyanin, C.F. Martos, M. Ter-Ovanesov, M. Peeters, Y.-J. Ko, S. Yalcin, M. Karthaus, J. Aparicio, V. Heinemann, P. Picard, D. BuryE. Drea, A. Sobrero

Research output: Contribution to journalArticle

Cite this

Riechelmann, R. P., Srimuninnimit, V., Bordonaro, R., Kavan, P., Di Bartolomeo, M., Maiello, E., Cicin, I., García-Alfonso, P., Chau, I., Fedyanin, M. Y., Martos, C. F., Ter-Ovanesov, M., Peeters, M., Ko, Y-J., Yalcin, S., Karthaus, M., Aparicio, J., Heinemann, V., Picard, P., ... Sobrero, A. (2019). Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). Clinical Colorectal Cancer, 18(3), 183. https://doi.org/10.1016/j.clcc.2019.05.003